Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.

Insmed Announces Results Of IPLEX(TM) Phase II Trial In Myotonic Muscular Dystrophy
Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined. The trial explored measures of endurance, using the six-minute walk test, muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin sensitivity, lipid metabolism, and safety and tolerability of IPLEX(TM).
News of the day
SLU Explores Best Ways To Use Standard TB Vaccine
In a study funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Saint Louis University"s Center for Vaccine Development is investigating whether the standard vaccine used in foreign countries against tuberculosis offers better protection as a shot, drink or combination of both.
Medical Devices

Oral Health Center Has Focus On Disease As A Whole

Australia"s premier research centre for all aspects of oral health will be established at the University of Adelaide thanks to a $2.4 million Federal Government grant. The new Centre of Clinical Research Excellence (CCRE) for Oral Health, which will be part of the University"s School of Dentistry, is being funded by the National Health and Medical Research Council (NHMRC). The CCRE Oral Health will be the first research centre of its kind in Australia to focus on all aspects of oral health research and its relationship with the broader health problems that are made worse by poor oral health. "The centre brings together a broad range of researchers with the aim of leading improvements in health outcomes for the community," says Professor Mark Bartold, Co-Director of the new centre. "Past research has focused on dental treatments to repair the damage caused by decay and periodontal disease, as well as the prevention of such diseases. But there has been a lack of research on the role of dental health in people"s overall well-being. A key focus for this new centre will be to investigate the interaction between systemic health and oral disease. "By researching oral health treatments that assist in the management of other diseases, we want to help patients as a whole. In this way, oral health treatments will be able to contribute to the management of patients" other general health conditions, such as cardiovascular disease, pulmonary/respiratory disease, diabetes and arthritis, which are all exacerbated by poor oral health," he says. Other key research areas for the CCRE Oral Health include: * Parental guidance and long-term oral health; * Improving dental treatment in Aboriginal children; * Genetic factors in dental development disorders; * Predicting and reducing mucosal toxicity during chemotherapy; * Use of stem cells in periodontal regeneration. Professor Bartold says the CCRE will also have major benefits for students and early career researchers. "With this new centre, we now have the opportunity to engage more PhD students and postdoctoral fellows in our work. This will be significant both in terms of postgraduate training as well as significantly increasing our research output," Professor Bartold says. Professor Mark Bartold University of Adelaide


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009